Document is current
Any future updates will be listed below
-
Authors
De Giovanni, Marco https://orcid.org/0000-0001-7521-3092
Inverso, Donato https://orcid.org/0000-0003-0987-3345
Iannacone, Matteo https://orcid.org/0000-0002-9370-2671
-
Funding
Funding for this research was provided by:
EC | ERC | HORIZON EUROPE European Research Council (101141363)
EC | ERC | HORIZON EUROPE European Research Council (101138728)
EC | ERC | HORIZON EUROPE European Research Council (101116224)
Fondazione AIRC per la ricerca sul cancro ETS (19891)
Fondazione AIRC per la ricerca sul cancro ETS (22737)
Fondazione AIRC per la ricerca sul cancro ETS (27564)
Fondazione AIRC per la ricerca sul cancro ETS (26183)
EC | Horizon 2020 Framework Programme (964481-IN2SIGHT)
Ministero dell'Università e della Ricerca (PE00000007 (INF-ACT))
Ministero dell'Università e della Ricerca (PRIN 2022FMESXL)
- License Information
-
More Information
Article History
Received: 31 July 2024
Revised: 14 August 2024
Accepted: 9 September 2024
First Online: 9 October 2024
Disclosure and competing interests statement
: MI participates in advisory boards/consultantship for Gilead Sciences, Asher Biotherapeutics, GentiBio, BlueJay Therapeutics, and Aligos Therapeutics. The remaining authors declare no competing interests. MI is inventor on patents filed, owned, and managed by Telethon Foundation and San Raffaele Scientific institute on technology related to the work presented here (PCT/EP2020/064933).
